Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
06 May 2020
Historique:
received: 22 01 2020
accepted: 26 04 2020
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 3 2 2021
Statut: epublish

Résumé

Spatial heterogeneity of prostate cancer-specific mortality in Pennsylvania remains unclear. We utilized advanced geospatial survival regressions to examine spatial variation of prostate cancer-specific mortality in PA and evaluate potential effects of individual- and county-level risk factors. Prostate cancer cases, aged ≥40 years, were identified in the 2004-2014 Pennsylvania Cancer Registry. The 2018 County Health Rankings data and the 2014 U.S. Environmental Protection Agency's Environmental Quality Index were used to extract county-level data. The accelerated failure time models with spatial frailties for geographical correlations were used to assess prostate cancer-specific mortality rates for Pennsylvania and by the Penn State Cancer Institute (PSCI) 28-county catchment area. Secondary assessment based on estimated spatial frailties was conducted to identify potential health and environmental risk factors for mortality. There were 94,274 cases included. The 5-year survival rate in PA was 82% (95% confidence interval, CI: 81.1-82.8%), with the catchment area having a lower survival rate 81% (95% CI: 79.5-82.6%) compared to the non-catchment area rate of 82.3% (95% CI: 81.4-83.2%). Black men, uninsured, more aggressive prostate cancer, rural and urban Appalachia, positive lymph nodes, and no definitive treatment were associated with lower survival. Several county-level health (i.e., poor physical activity) and environmental factors in air and land (i.e., defoliate chemical applied) were associated with higher mortality rates. Spatial variations in prostate cancer-specific mortality rates exist in Pennsylvania with a higher risk in the PSCI's catchment area, in particular, rural-Appalachia. County-level health and environmental factors may contribute to spatial heterogeneity in prostate cancer-specific mortality.

Sections du résumé

BACKGROUND BACKGROUND
Spatial heterogeneity of prostate cancer-specific mortality in Pennsylvania remains unclear. We utilized advanced geospatial survival regressions to examine spatial variation of prostate cancer-specific mortality in PA and evaluate potential effects of individual- and county-level risk factors.
METHODS METHODS
Prostate cancer cases, aged ≥40 years, were identified in the 2004-2014 Pennsylvania Cancer Registry. The 2018 County Health Rankings data and the 2014 U.S. Environmental Protection Agency's Environmental Quality Index were used to extract county-level data. The accelerated failure time models with spatial frailties for geographical correlations were used to assess prostate cancer-specific mortality rates for Pennsylvania and by the Penn State Cancer Institute (PSCI) 28-county catchment area. Secondary assessment based on estimated spatial frailties was conducted to identify potential health and environmental risk factors for mortality.
RESULTS RESULTS
There were 94,274 cases included. The 5-year survival rate in PA was 82% (95% confidence interval, CI: 81.1-82.8%), with the catchment area having a lower survival rate 81% (95% CI: 79.5-82.6%) compared to the non-catchment area rate of 82.3% (95% CI: 81.4-83.2%). Black men, uninsured, more aggressive prostate cancer, rural and urban Appalachia, positive lymph nodes, and no definitive treatment were associated with lower survival. Several county-level health (i.e., poor physical activity) and environmental factors in air and land (i.e., defoliate chemical applied) were associated with higher mortality rates.
CONCLUSIONS CONCLUSIONS
Spatial variations in prostate cancer-specific mortality rates exist in Pennsylvania with a higher risk in the PSCI's catchment area, in particular, rural-Appalachia. County-level health and environmental factors may contribute to spatial heterogeneity in prostate cancer-specific mortality.

Identifiants

pubmed: 32375682
doi: 10.1186/s12885-020-06902-5
pii: 10.1186/s12885-020-06902-5
pmc: PMC7203834
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

394

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR002014
Pays : United States
Organisme : Highmark Incorporation Grant
ID : None

Références

Br J Cancer. 2008 Dec 2;99(11):1786-93
pubmed: 18985045
Geospat Health. 2017 Nov 28;12(2):611
pubmed: 29239571
Soc Sci Med. 2017 Nov;193:1-7
pubmed: 28985516
Clin Colorectal Cancer. 2019 Jun;18(2):e261-e274
pubmed: 30713133
Springerplus. 2016 Sep 13;5(1):1548
pubmed: 27652121
Am J Prev Med. 2016 Feb;50(2):129-35
pubmed: 26526164
PLoS One. 2017 Mar 27;12(3):e0174548
pubmed: 28346484
Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1265-1274
pubmed: 28751476
Prostate Cancer Prostatic Dis. 2016 Dec;19(4):395-397
pubmed: 27431496
Gynecol Oncol. 2019 Aug;154(2):405-410
pubmed: 31208738
Exp Gerontol. 2009 Mar;44(3):190-200
pubmed: 19007875
Ann Intern Med. 2012 Jul 17;157(2):120-34
pubmed: 22801674
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):250-8
pubmed: 26819264
J Health Commun. 2010;15 Suppl 3:78-91
pubmed: 21154085
Rural Sociol. 2017 Sep;82(3):411-443
pubmed: 29556111
Environ Health. 2014 May 22;13(1):39
pubmed: 24886426
Prostate. 2017 Jun;77(8):878-887
pubmed: 28261834
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):57-64
pubmed: 25527697
Cancer Causes Control. 2015 Oct;26(10):1375-92
pubmed: 26245248
Cancer. 2017 Nov 15;123(22):4449-4457
pubmed: 28727136
Am J Public Health. 2011 Dec;101 Suppl 1:S277-85
pubmed: 21836111
Am J Psychiatry. 2008 Jul;165(7):820-9
pubmed: 18519522
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):632-641
pubmed: 27956436
J Natl Cancer Inst. 2003 Nov 19;95(22):1702-10
pubmed: 14625261
Eur Urol Focus. 2018 Jan;4(1):121-127
pubmed: 29162421
J Appl Stat. 2011 Mar;38(2):591-603
pubmed: 21475617
Stat Methods Med Res. 2016 Apr;25(2):793-806
pubmed: 23117407
Am J Public Health. 2013 Apr;103(4):727-32
pubmed: 23409874
J Rural Health. 2019 Mar;35(2):176-188
pubmed: 30830984
Occup Environ Med. 2019 Sep;76(9):632-643
pubmed: 31413186
Ecotoxicol Environ Saf. 2018 Nov 30;164:61-68
pubmed: 30098506
JAMA Oncol. 2019 Jul 1;5(7):975-983
pubmed: 31120534
Am J Ind Med. 2003 Feb;43(2):227-33
pubmed: 12541279
JAMA Netw Open. 2018 Aug 3;1(4):e181235
pubmed: 30646114
Stat Med. 1997 Apr 15;16(7):791-801
pubmed: 9131766
Am J Mens Health. 2013 Jul;7(4):306-16
pubmed: 23339130
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):590-5
pubmed: 15767335
World Neurosurg. 2017 Jul;103:186-193
pubmed: 28366748
J Rural Health. 2017 Sep;33(4):375-381
pubmed: 27602545
Soc Sci Med. 2015 Oct;142:9-18
pubmed: 26281022

Auteurs

Ming Wang (M)

Department of Public Health Sciences, Penn State College of Medicine and Cancer Institute, 90 Hope Drive, Hershey, PA, 17033, USA. muw22@psu.edu.
Penn State Cancer Institute, Hershey, PA, USA. muw22@psu.edu.

Emily Wasserman (E)

Department of Public Health Sciences, Penn State College of Medicine and Cancer Institute, 90 Hope Drive, Hershey, PA, 17033, USA.

Nathaniel Geyer (N)

Department of Public Health Sciences, Penn State College of Medicine and Cancer Institute, 90 Hope Drive, Hershey, PA, 17033, USA.

Rachel M Carroll (RM)

Department of Mathematics and Statistics, the University of North Carolina at Wilmington, Wilmington, NC, USA.

Shanshan Zhao (S)

Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.

Lijun Zhang (L)

Penn State Cancer Institute, Hershey, PA, USA.
Penn State Institute of Personalized Medicine, Hershey, PA, USA.

Raymond Hohl (R)

Penn State Cancer Institute, Hershey, PA, USA.
Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
Department of Pharmacology, Penn State College of Medicine, Hershey, PA, USA.

Eugene J Lengerich (EJ)

Department of Public Health Sciences, Penn State College of Medicine and Cancer Institute, 90 Hope Drive, Hershey, PA, 17033, USA.
Penn State Cancer Institute, Hershey, PA, USA.
Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.

Alicia C McDonald (AC)

Department of Public Health Sciences, Penn State College of Medicine and Cancer Institute, 90 Hope Drive, Hershey, PA, 17033, USA.
Penn State Cancer Institute, Hershey, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH